Physician profile
Sam Mathew
NPI 1619198082
$2,618.47
in general payments reported to CMS, 2019-2025
38 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $725 · 2022: $852 · 2023: $511 · 2024: $254 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.49 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $663.40 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
| Astellas Pharma US INC | $478.31 | 2021-2023 | Xospata |
| Jazz Pharmaceuticals INC. | $114.26 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $103.72 | 2022-2024 | Darzalex, Carvykti |
| Amgen INC. | $99.95 | 2022 | |
| Acrotech Biopharma INC. | $96.12 | 2021-2023 | Beleodaq |
| Merck Sharp & Dohme LLC | $86.68 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $76.21 | 2021-2025 | Xpovio |
| Blueprint Medicines Corporation | $66.24 | 2021-2024 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $61.63 | 2022-2024 | Tavalisse, Rezlidhia |
| Legend Biotech USA INC. | $47.49 | 2023-2025 | Carvykti |
| Genzyme Corporation | $47.39 | 2022-2024 | |
| Morphosys, US INC. | $46.82 | 2023 | Monjuvi |
| Glaxosmithkline, LLC. | $46.58 | 2022-2025 | Ojjaara |
| Dova Pharmaceuticals | $44.82 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.12 | 2021-2023 | |
| Cti Biopharma Corp. | $34.17 | 2022 | |
| Taiho Oncology, INC. | $32.16 | 2021 | |
| Adaptive Biotechnologies Corporation | $29.83 | 2023 | Clonoseq |
| Abbvie INC. | $29.64 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $28.70 | 2023 | Imbruvica |
| Stemline Therapeutics INC. | $27.62 | 2025 | Elzonris |
| Ipsen Biopharmaceuticals, INC | $25.46 | 2023 | Tazverik |
| Regeneron Healthcare Solutions, INC. | $24.66 | 2021 | |
| Syndax Pharmaceuticals, INC. | $24.29 | 2025 | |
| Exelixis INC. | $24.04 | 2025 | Cabometyx |
| Janssen Biotech, INC. | $23.00 | 2025 | Darzalex, Tecvayli, Talvey |
| Servier Pharmaceuticals LLC | $21.82 | 2024 | |
| Adc Therapeutics America, INC. | $21.13 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.01 | 2022 | |
| Sobi, INC | $20.30 | 2024 | |
| Btg International INC. | $19.61 | 2021 | |
| Menarini Silicon Biosystems, INC. | $19.28 | 2024 | |
| Sanofi-Aventis U.S. LLC | $18.37 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $17.90 | 2021 | |
| Pfizer INC. | $16.68 | 2022 | |
| Epizyme, INC. | $15.09 | 2021 | |
| Iovance Biotherapeutics, INC. | $5.97 | 2024 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.